Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prophylactic photobiomodulation to reduce oral mucositis in head and neck cancer: an observational study.
Ferrari R, Felizardo AC, Siqueira L, Abreu L, Araújo D, Araujo L, Fernandes T, Lopes C, Peixoto R, Melo B, Dias AM, Silva R, Laloni MT, Ferrari B, Ferreira CGM, Fregnani E, William WN Jr, Bergerot CD. Ferrari R, et al. Among authors: william wn jr. Support Care Cancer. 2025 Oct 14;33(11):944. doi: 10.1007/s00520-025-10020-y. Support Care Cancer. 2025. PMID: 41087749
Challenges and Opportunities in Head and Neck Cancer Research in Developing Countries: Insights From a Fireside Chat.
Chaves ALF, Kowalski LP, Marta GN, Santos-Silva AR, Vieira Muniz L, Mak MP, Gossling G, Guimaraes VS, Oliveira de Castro Junior D, de Oliveira TB, Lima CSP, Traldi Macedo L, Jacinto AA, Harada G, Barbosa MVDR, Santos IC, Batalha Filho ES, De Castro Junior G, de Marchi PRM, Matos LL, Curado MP, Mehanna H, William WN Jr. Chaves ALF, et al. Among authors: william wn jr. JCO Glob Oncol. 2025 May;11:e2500207. doi: 10.1200/GO-25-00207. Epub 2025 Sep 9. JCO Glob Oncol. 2025. PMID: 40924971
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. Machiels JP, et al. Among authors: william wn jr. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13. Future Oncol. 2025. PMID: 40511820 Free PMC article.
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Zhou N, et al. Among authors: william wn jr. J Immunother Cancer. 2024 Oct 23;12(10):e009677. doi: 10.1136/jitc-2024-009677. J Immunother Cancer. 2024. PMID: 39448200 Free PMC article. Clinical Trial.
The impact of colonialism on head and neck cancer in Brazil: a historical essay focussing on tobacco, alcohol and slavery.
Figueiredo Lebre Martins BN, Dos Santos ES, Fonseca FP, William WN Jr, Bueno de Oliveira T, Marta GN, Freitas Chaves AL, Prado-Ribeiro AC, Ayo-Yusuf O, Curado MP, Saes AM, Kowalski LP, Santos-Silva AR; Latin American Cooperative Oncology Group; Brazilian Group of Head and Neck Cancer. Figueiredo Lebre Martins BN, et al. Among authors: william wn jr. Lancet Reg Health Am. 2024 Feb 9;31:100690. doi: 10.1016/j.lana.2024.100690. eCollection 2024 Mar. Lancet Reg Health Am. 2024. PMID: 38370581 Free PMC article. Review.
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Hanna GJ, et al. Among authors: william wn jr. JAMA Oncol. 2024 Jan 1;10(1):32-41. doi: 10.1001/jamaoncol.2023.4853. JAMA Oncol. 2024. PMID: 37971722 Free PMC article.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Passaro A, et al. Among authors: william wn jr. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879444 Free article. Clinical Trial.
112 results